Impact of the Interval Between Neoadjuvant Chemotherapy and Gastrectomy on Short- and Long-Term Outcomes for Patients with Advanced Gastric Cancer.
Augustinas BaušysToomas ÜmarikMartynas LukstaArvo ReinsooRokas RackauskasGiedre AnglickieneMarius KryzauskasKristina TõnismäeVeslava SeninaDmitrij SeininRimantas BausysKestutis StrupasPublished in: Annals of surgical oncology (2021)
This study suggests that an interval of more than 30 days between the end of NAC and gastrectomy is associated with a higher mPR rate, the same oncologic safety of surgery, and similar morbidity and mortality.
Keyphrases
- neoadjuvant chemotherapy
- locally advanced
- lymph node
- sentinel lymph node
- rectal cancer
- minimally invasive
- transcription factor
- coronary artery bypass
- radiation therapy
- metabolic syndrome
- prostate cancer
- early stage
- coronary artery disease
- acute coronary syndrome
- surgical site infection
- weight loss
- genome wide analysis